Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 334

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Cytomegalovirus infection in transplant recipients

Open access
Azevedo, Luiz Sergio, Pierrotti, Lígia Camera, Abdala, Edson, Costa, Silvia Figueiredo, Strabelli, Tânia Mara Varejão, Campos, Silvia Vidal, Ramos, Jéssica Fernandes, Latif, Acram Zahredine Abdul, Litvinov, Nadia, Maluf, Natalya Zaidan, Filho, Helio Hehl Caiaffa, Pannuti, Claudio Sergio, Lopes, Marta Heloisa, dos Santos, Vera Aparecida, da Cruz Gouveia Linardi, Camila, Yasuda, Maria Aparecida Shikanai, de Sousa Marques, Heloisa Helena·2015·Clinics

Abstract

Cytomegalovirus infection is a frequent complication after transplantation. This infection occurs due to transmission from the transplanted organ, due to reactivation of latent infection, or after a primary infection in seronegative patients and can be defined as follows: latent infection, active infection, viral syndrome or invasive disease. This condition occurs mainly between 30 and 90 days after transplantation. In hematopoietic stem cell transplantation in particular, infection usually occurs within the first 30 days after transplantation and in the presence of graft-versus-host disease. The major risk factors are when the recipient is cytomegalovirus seronegative and the donor is seropositive as well as when lymphocyte-depleting antibodies are used. There are two methods for the diagnosis of cytomegalovirus infection: the pp65 antigenemia assay and polymerase chain reaction. Serology has no value for the diagnosis of active disease, whereas histology of the affected tissue and bronchoalveolar lavage analysis are useful in the diagnosis of invasive disease. Cytomegalovirus disease can be prevented by prophylaxis (the administration of antiviral drugs to all or to a subgroup of patients who are at higher risk of viral replication) or by preemptive therapy (the early diagnosis of viral replication before development of the disease and prescription of antiviral treatment to prevent the appearance of clinical disease). The drug used is intravenous or oral ganciclovir; oral valganciclovir; or, less frequently, valacyclovir. Prophylaxis should continue for 90 to 180 days. Treatment is always indicated in cytomegalovirus disease, and the gold-standard drug is intravenous ganciclovir. Treatment should be given for 2 to 3 weeks and should be continued for an additional 7 days after the first negative result for viremia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.6061/clinics/2015(07)09

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 38 references

Cited by

See all 334

Metadata

Authors
Azevedo, L. S., Pierrotti, L. C., Abdala, E., Costa, S. F., Strabelli, T. M. V., Campos, S. V., Ramos, J. F., Latif, A. Z. A., Litvinov, N., Maluf, N. Z., Filho, H. H. C., Pannuti, C. S., Lopes, M. H., dos Santos, V. A., da Cruz Gouveia Linardi, C., Yasuda, M. A. S., & de Sousa Marques, H. H.
Venue
Clinics
Publisher
Elsevier BV
Published
2015-07
Volume
70
Issue
7
Pages
515-523
ISSN
1807-5932 (ISSN-L)
OpenAlex
W1506247664
Cited by
334
References
38
FWCI
9.17
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cytomegalovirus infection in transplant recipients. https://app.cochat.ai/papers/10.6061/clinics/2015(07)09
The paper
Azevedo, L. S., Pierrotti, L. C., Abdala, E., Costa, S. F., Strabelli, T. M. V., Campos, S. V., Ramos, J. F., Latif, A. Z. A., Litvinov, N., Maluf, N. Z., Filho, H. H. C., Pannuti, C. S., Lopes, M. H., dos Santos, V. A., da Cruz Gouveia Linardi, C., Yasuda, M. A. S., & de Sousa Marques, H. H. (2015). Cytomegalovirus infection in transplant recipients. Clinics. https://doi.org/10.6061/clinics/2015(07)09

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.